We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Primary pulmonary leiomyosarcoma: A case report.
- Authors
XIAONA XIE; YANFAN CHEN; CHENG DING; XIAOMING YU; LIZHEN ZOU; BOTAO XU; LIANGXING WANG; XIAOYING HUANG
- Abstract
Primary pulmonary leiomyosarcoma (PPL) is an extremely rare malignant tumor. It has been revealed that PPL may originate from the smooth muscle of the pulmonary parenchyma, pulmonary arteries and bronchi. Patients with PPL may be asymptomatic or present with symptoms similar to those observed in other primary lung tumors. The present study reports the case of a 48-year-old man who presented with a lung mass and underwent a right upper-middle lobe bronchoscope tumor resection. The patient was subsequently diagnosed with PPL. Following the bronchoscopic tumor resection, chemotherapy was administered to the patient; however, the patient succumbed to the disease after the second cycle of chemotherapy. Introduction Leiomyosarcomas are tumors of the smooth muscle cells that may originate in any location, but most often arise in the uterus, gastrointestinal tract and soft tissue. Primary pulmonary leiomyosarcoma (PPL) is an extremely rare malignant mesenchymal tumor that appears to originate from the smooth muscle cells of the bronchial and blood vessel wall. PPL accounts for <0.5% of all malignant pulmonary tumors (1). A previous study reported a 5-year survival rate of 60% for PPL (2). The tumors may be treated using surgical resection, which is the primary and definitive mode of treatment. Surgical strategies consist of lobectomy, pneumonectomy and bronchial sleeve resection. The role of other treatment methods has yet to be defined; however, radiochemotherapy is recommended in cases of incomplete resection and malignancy (1). A definitive diagnosis of PPL is provided following pathological examination of a tumor sample. Early detection and complete surgical resection of PPL have been demonstrated to significantly contribute to an increased survival time of patients with the disease (3). Written informed consent was obtained from the patient.
- Subjects
LEIOMYOSARCOMA; LUNG cancer treatment; CHEMORADIOTHERAPY; PNEUMONECTOMY; LOBECTOMY (Lung surgery); BRONCHOSCOPY
- Publication
Oncology Letters, 2016, Vol 11, Issue 3, p1807
- ISSN
1792-1074
- Publication type
Case Study
- DOI
10.3892/ol.2016.4131